Capricor Therapeutics Inc (NASDAQ:CAPR), a clinical-stage biotechnology company, reported its fourth quarter and full-year 2025 financial results, delivering a quarterly loss that was wider than analyst expectations. The market’s immediate reaction was mutedly negative, with shares trading down approximately 1.3% in after-hours activity following the release.
Earnings Miss Amid Pivotal Regulatory Period
For the quarter ending December 31, 2025, Capricor reported no revenue, which was in line with analyst estimates of $0.0. The focus for investors, however, was squarely on the company’s net loss. Capricor posted a non-GAAP earnings per share (EPS) loss of $0.62, which fell short of the consensus analyst estimate of a $0.55 loss.
The key metrics from the report are as follows:
- Reported Q4 2025 Revenue: $0.0 million (in line with estimates of $0.0 million)
- Reported Q4 2025 Non-GAAP EPS: -$0.62 (missed estimates of -$0.55)
- After-Market Reaction: Shares declined ~1.3%
This earnings miss comes at a critical juncture for the company, which is funneling its resources into the development and regulatory review of its lead candidate, deramiocel (CAP-1002), for the treatment of Duchenne muscular dystrophy (DMD).
Corporate Update Overshadows Financials
The financial results were accompanied by a corporate update that highlighted the company's primary near-term catalyst. The most significant news for investors is the ongoing regulatory review of deramiocel. The Biologics License Application (BLA) is currently under review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) target action date set for August 22, 2026. This date represents a potential landmark approval decision for the company.
Furthermore, Capricor noted that its pivotal HOPE-3 Phase 3 trial for deramiocel achieved its primary and secondary endpoints, providing the clinical foundation for the BLA submission. The company’s update reinforces that its current valuation and investor sentiment are largely tied to the progression of this single, high-stakes regulatory pathway rather than its present financial performance, which is typical for a pre-commercial biotech firm.
Forward-Looking Estimates and Market Perspective
Looking ahead, analyst projections underscore the transformative potential of a successful deramiocel launch, while also reflecting the substantial costs and risks inherent in the current stage. For the full year 2026, analysts are modeling a significant net loss but are also forecasting the company’s first substantial revenue.
- Estimated FY 2026 Revenue: $106.5 million
- Estimated FY 2026 EPS: -$1.57
For the upcoming first quarter of 2026, expectations remain in a pre-revenue stage, with estimates pointing to another period of investment.
- Estimated Q1 2026 Revenue: $0.0 million
- Estimated Q1 2026 EPS: -$0.48
The modest negative after-hours move following the earnings release suggests the market had largely anticipated the quarterly loss. Investor attention appears firmly fixed on the long-term outlook and the binary event of the FDA’s decision in August, rather than a quarterly earnings variance. The path to commercialization is costly, and the reported EPS miss is a reflection of those ongoing operational expenses.
For a detailed view of Capricor’s historical earnings and future analyst projections, you can review the earnings history and analyst estimates.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy, sell, or hold any security, or an endorsement of any investment strategy. Investing in biotechnology stocks, especially clinical-stage companies like Capricor, involves a high degree of risk, including the potential loss of principal. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
